Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05872295 · ClinicalTrials.gov registry record · Phase 1
IKS014 in Advanced Solid Tumors That Express HER2
A Phase 1 study of Breast Cancer and Gastric Cancer, sponsored by Iksuda Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 165
- Enrollment target
- 12
- Study locations
NCT05872295 is a Phase 1 study of Breast Cancer and Gastric Cancer that is actively recruiting participants, run by Iksuda Therapeutics. The registered enrollment target is 165 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 12 study locations across 7 states.
The verdict
NCT05872295, a Phase 1 study of Breast Cancer and Gastric Cancer, is actively recruiting participants, sponsored by Iksuda Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 165 participants
- Enrollment target
- 12
- Study locations
Study Summary
This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate, in patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG IKS014
Study Locations (12)
New South Wales
- Concord Repatriation General Hospital Medical Oncology Clinical Trials Unit - Concord
- Macquarie University - Sydney
- Westmead Hospital - Westmead
Other
- Auckland City Hospital - Auckland
- National Cancer Centre Singapore - Singapore
- Tan Tock Seng Hospital - Singapore
Victoria
- Peninsula & South Eastern Haematology and Oncology Group (PSEHOG) - Frankston
- Alfred Health - Melbourne
California
- Hoag Memorial Hospital Presbyterian - Newport Beach
Massachusetts
- Dana Farber Cancer Institute - Boston
Tennessee
- Tennessee Oncology - Nashville
Western Australia
- Linear Clinical Research - Nedlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2023-09-14 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05872295
The ClinicalTrials.gov registry entry for NCT05872295 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Iksuda Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which IKS014 is the first listed.
NCT05872295 reports 12 study locations spanning 7 distinct geographic areas - top geographies include New South Wales, Other, Victoria.
Frequently Asked Questions
What is clinical trial NCT05872295 about?
NCT05872295 is a clinical study titled "IKS014 in Advanced Solid Tumors That Express HER2". This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate, in patients with advanced solid tumors.
What is the current status of trial NCT05872295?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 165 participants. The study started on 2023-09-14. Estimated completion is 2027-09.
What conditions does trial NCT05872295 study?
This clinical trial studies the following conditions: Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer.
What interventions are being tested in trial NCT05872295?
The interventions under investigation include: IKS014 (DRUG).
Who is sponsoring clinical trial NCT05872295?
This trial is sponsored by Iksuda Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05872295 being conducted?
This trial has 12 study locations across California, Massachusetts, Tennessee, New South Wales, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.